Amgen Inc on Wednesday said it filed with U.S. health regulators seeking approval to sell its first biosimilar drug, which would be a less expensive alternative to AbbVie's Humira, the world's top-selling prescription medicine.
Amgen said its drug, ABP 501, has demonstrated clinical equivalence and comparable safety to Humira (adalimumab) in late stage clinical trials for rheumatoid arthritis and the skin condition plaque psoriasis.
Also read: Caterpillar Says Sales Woes Could Linger
16:36 AT&T, Time Warner poised to lobby lawmakers, regulators on proposed $85-billion merger25
12:23 Lockheed Martin's quarterly profit handily beats estimates28
11:41 Caterpillar earnings: 85 cents per share, vs expected EPS of 76 cents24
00:02 AT&T Aims for an Empire in Merger Talks With Time Warner13